Merck may have a competition for ever-scarce BCG

Off addiction, Biotech, biotechnology, Business, drug development, drug prices, drug pricing, H5N1 Bird Flu, Health, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, policy, Politics, public health, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning! Today, we learn more about studying tumors at the International Space Station, study the buzzy Amgen weight loss drug MariTide, and find a lawsuit in which a former Spark Therapeutics executive is accusing ex-colleagues of sexism.

Read the rest…

Read Original Article: Merck may have a competition for ever-scarce BCG »

About The Author